{'fraction_non_alphanumeric': 0.024478694469628286, 'fraction_numerical': 0.009972801450589302, 'mean_word_length': 5.814814814814815, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Recent advances in the development of celecoxib analogs as anticancer agents: A review

Celecoxib is a nonsteroidal anti‐inflammatory drug (NSAID) designed to be a selective cyclooxygenase‐2 (COX‐2) inhibitor. It was approved by the U.S. Food and Drug Administration for the treatment of inflammatory diseases such as osteoarthritis and rheumatoid arthritis. Additionally, celecoxib demonstrated potent antitumor and chemopreventive effects in vitro, in vivo, and in patients. The mechanism of celecoxib's chemopreventive effect is still not fully identified, but it is assumed to be multifactorial. Celecoxib's anticancer activity has been described both as independent of and dependent on its COX‐2 inhibitory activity. The current review summarizes the recent advances published between 2000 and 2022 on the structure‐based optimization of celecoxib to develop compounds with promising anticancer activity. The structure–activity relationships of celecoxib analogs are discussed, which may be beneficial in the design and development of novel analogs as potent antiproliferative agents in the future.